Key metrics and charts across all fundamental categories.
Stock price and market valuation
MRNA trades at $59.345, a 109.3% increase year-over-year. Market capitalization stands at $23.44B, up 114.2% from the prior year. Track MRNA price trends and market cap history to understand how the market values this company over time.
Revenue and earnings growth across quarters
$2.23B in TTM revenue declined 30.0% YoY, reaching $389.00M last quarter. TTM EBITDA of $-3.18B on operating income of $-1.39B shows growth is flowing through. However, net income is negative at $3.19B — growth is not yet reaching the bottom line. Revenue is contracting — assess whether this is cyclical or structural.
Assets, cash, debt, and leverage
With $11.49B in assets and $590.00M in long-term debt, the D/E of 0.1 shows a conservative capital structure — the company has a strong financial cushion to weather downturns.
Price multiples and return ratios
P/S of 10.5x and P/B of 3.2x. A high P/S suggests growth expectations are priced in.
Operating efficiency and return metrics
Op. margin of -356.8% is up 615.4% YoY — cost efficiency is improving. Net margin at -345.2% and gross margin of -145.5%. Negative ROE of -43.1% indicates shareholder value is being eroded.
Free cash flow, earnings quality, and capital allocation
FCF of $-692.00M on $-630.00M in operating cash flow. The FCF / Net Income ratio of 0.2x indicates partial cash conversion — earnings quality needs attention. Cash reserves of $1.91B provide financial flexibility. Shares outstanding rose 2.3% YoY — shareholder dilution is eroding per-share value.
